首页> 外文学位 >Challenges in developing an oral vaccine for canine parvovirus type 2.
【24h】

Challenges in developing an oral vaccine for canine parvovirus type 2.

机译:开发2型犬细小病毒口服疫苗的挑战

获取原文
获取原文并翻译 | 示例

摘要

An oral vaccine to prevent disease caused by canine parvovirus type 2 (CPV-2) would provide certain advantages for vaccinating domestic, wild, exotic and farm raised species susceptible to CPV-2 and antigenically related viruses. Modified live and killed vaccine, with or without oral adjuvants, including plant vectored CPV-2, killed virus with various adjuvant systems, and virus conjugated to an adjuvant, as well as poxvirus vectored CPV-2 were developed or obtained and given orally. Many challenges and failures were encountered, thus it was not possible to develop an oral vaccine for CPV-2.; Transgenic plants expressing the capsid protein, VP1 of CPV-2, were unsuccessful. A novel spontaneous frame-shift mutation caused by the toxicity in E. cola and a new deletion mutation model was proposed. A hot spot specific sequence led to the mutation.; Non-infectious (killed) parvovirus, with and without multiple adjuvants, was used to vaccinate pups orally. Pups were vaccinated orally with 1 to 2 ml of these various mixtures with 2 or more doses given at 2-3 week intervals. None of the orally vaccinated pups developed an immune response to CPV-2 irrespective of the adjuvants nor the number of doses of vaccines.; Multiple doses of MLV CPV-2 vaccines also failed to stimulate a local or systemic antibody response when given orally. In contrast, when these same vaccines were given parenterally (e.g. subcutaneously or IM) all animals developed an antibody. Vaccine virus was more sensitive to inactivation at low pH (pH 3) compared to virulent CPV-2, a possible reason why it failed to immunize when given orally.; A method that appeared certain to immunize dogs orally was a raccoon poxvirus (RCNV) vector that reportedly contained the VP2 construct of feline parvovirus (FPV). However, the FPV construct in RCNV must have been spontaneously expelled as it was not found by either PCR or nested PCR, and VP2 was not found by Western blots.; From the present and previous studies it was concluded that dogs could not be orally immunized with CVP-2 vaccine. We conclude that most methods successfully used to orally immunize animals for certain viruses were unsuccessful with CPV-2.
机译:预防由2型犬细小病毒引起的疾病的口服疫苗将为接种对CPV-2和抗原相关病毒敏感的家养,野生,外来和农场饲养的物种提供某些优势。研制或获得了经修饰的活疫苗和灭活疫苗,可口服或不口服口服佐剂,包括植物载体的CPV-2,具有各种佐剂系统的杀灭病毒,与佐剂缀合的病毒以及痘病毒载体的CPV-2。遇到了许多挑战和失败,因此不可能开发用于CPV-2的口服疫苗。表达衣壳蛋白CPV-2 VP1的转基因植物未成功。提出了一种新的由可乐中毒性引起的自发移码突变和新的缺失突变模型。热点特异性序列导致突变。带有或不带有多种佐剂的非感染性(杀灭性)细小病毒被用来给幼犬口服疫苗。将幼犬口服1至2毫升的这些各种混合物,每2-3周间隔注射2剂或更多剂。不论佐剂或疫苗剂量的多少,口服疫苗的幼崽均未对CPV-2产生免疫反应。口服时,多剂量的MLV CPV-2疫苗也未能刺激局部或全身性抗体反应。相反,当胃肠外(例如皮下或IM)给予这些相同的疫苗时,所有动物都产生抗体。与强毒的CPV-2相比,疫苗病毒在低pH(pH 3)下对失活更为敏感,这可能是口服给予疫苗未能免疫的可能原因。一种看来可以口服免疫狗的方法是浣熊痘病毒(RCNV)载体,据报道该载体包含猫细小病毒(FPV)的VP2构建体。然而,RCNV中的FPV构建体必须被自发排出,因为无论是通过PCR还是巢式PCR都没有发现它,并且通过Western印迹也没有发现VP2。从目前和以前的研究可以得出结论,不能用CVP-2疫苗对狗进行口服免疫。我们得出的结论是,成功用于口服免疫某些病毒的动物的大多数方法均不能成功使用CPV-2。

著录项

  • 作者

    Guo, Yuyuan.;

  • 作者单位

    The University of Wisconsin - Madison.;

  • 授予单位 The University of Wisconsin - Madison.;
  • 学科 Biology Genetics.; Biology Veterinary Science.; Health Sciences Immunology.
  • 学位 Ph.D.
  • 年度 2006
  • 页码 149 p.
  • 总页数 149
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 遗传学;动物学;预防医学、卫生学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号